Exercise Dose and Metformin for Vascular Health in Adults With Metabolic Syndrome
Status:
Active, not recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
Health organizations recommend exercise in an intensity based manner to promote
cardiovascular adaptation and prevent disease. Metformin is a common anti-diabetes medication
that reduces future type 2 diabetes and cardiovascular disease (CVD) risk. However, the
optimal dose of exercise to be combined with metformin for vascular health remains unknown.
The purpose of this study is to evaluate whether combining high or low intensity exercise
with metformin has the potential to outperform either exercise intensity alone on blood flow
across the arterial tree as well as impact insulin action in individuals with metabolic
syndrome. Identification of such outcomes will indicate 1) whether and how metformin should
be combined with physical activity for CVD prevention, 2) provide the first indication of
whether exercise intensity reduces CVD risk via multi-level vasculature function vs.
metabolic insulin action, and 3) provide a rational early treatment for people with metabolic
syndrome to prevent/treat type 2 diabetes and CVD.